Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Andexxa (Ondexxya) Market Size, Value And Growth Trajectory Through 2030
Historical expansion was driven by the extensive application of factor Xa inhibitors, urgent bleeding events, the regulatory approval of reversal agents, the demand for hospital critical care, and an aging demographic.
The expansion observed in the projected period is due to a rise in cardiovascular disease cases, an increase in anticoagulant medication prescriptions, the broadening of trauma care services, enhanced emergency protocols, and a surge in surgical interventions.
Significant developments anticipated during the forecast period include a growing requirement for anticoagulant reversal solutions, advances in emergency bleeding management, critical care therapies centralized in hospitals, a greater uptake of factor Xa inhibitors, and a strong focus on rapid hemostasis solutions.
Get A Free Sample Report With In-Depth Market Insights:
Andexxa (Ondexxya) Market Growth Catalysts And Demand Drivers
The growing incidence of bleeding disorders is set to boost the andexxa (ondexxya) market. Bleeding disorders are medical conditions where blood clotting is impaired, resulting in excessive or prolonged bleeding. The rise in these disorders can be attributed to better diagnostic methods, increased public awareness, genetic factors, and an aging population, all of which enhance their recognition and detection. Andexxa (Ondexxya) is crucial for managing bleeding disorders as it swiftly reverses the anticoagulant effects of factor Xa inhibitors, thereby preventing life-threatening hemorrhage in emergency scenarios. For instance, according to the National Blood Authority, an Australia-based blood management agency, in July 2025, there were 2,797 patients living with von Willebrand disease (VWD) in 2023–2024, a notable increase from 2,669 patients in 2022–2023. Thus, the increasing prevalence of bleeding disorders is a significant driver for the growth of the andexxa (ondexxya) market. The expanding geriatric population is anticipated to fuel the growth of the andexxa (ondexxya) market. The geriatric population includes individuals aged 65 and above, who often face various age-related health challenges like chronic diseases, cognitive decline, and mobility issues. This demographic is increasing globally due to enhanced life expectancy and advancements in healthcare. Andexxa (Ondexxya) is particularly beneficial for the geriatric population because it helps reverse bleeding caused by blood thinners, which older adults frequently use for conditions such as atrial fibrillation. For example, a report published by the World Health Organization (WHO), a Switzerland-based agency focused on international public health, stated in October 2022 that by 2030, one in six people worldwide is expected to be 60 or older. Furthermore, by 2050, the global population aged 60 or older will reach 2.1 billion people. Consequently, the increasing geriatric population is driving the growth of the andexxa (ondexxya) market.
Andexxa (Ondexxya) Market Breakdown By Product Type And Application
The andexxa (ondexxya) market covered in this report is segmented –
1) By Indication: Reversal Of Bleeding Caused By Factor Xa Inhibitors, Acute Major Bleeding Events, Emergency Surgery Or Procedures
2) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies
3) By End User: Adult, Geriatric, Pediatric
Andexxa (Ondexxya) Market Trends Shaping Long-Term Demand
Leading firms within the Andexxa market are concentrating on creating sophisticated anticoagulant reversal treatments to improve patient well-being during severe bleeding episodes. This type of therapy specifically counters the action of anticoagulant medications, swiftly re-establishing normal blood clotting and mitigating the danger of life-threatening hemorrhages. A notable example occurred in January 2024, when AstraZeneca India gained CDSCO authorization to bring in and commercialize andexanet alfa for managing critical or persistent bleeding induced by Factor Xa inhibitors like apixaban and rivaroxaban. The recently approved therapy involves an initial intravenous bolus administered over 15–30 minutes, succeeded by a 2-hour infusion. Clinical research concerning significant bleeding has shown andexanet alfa to be effective and safe, enabling the prompt resumption of anticoagulation post-event. It is also well-tolerated and fills a vital gap for individuals taking novel oral anticoagulants.
Andexxa (Ondexxya) Market Company Landscape And Competitive Strategy
Major companies operating in the andexxa (ondexxya) market are AstraZeneca Plc
View The Full Andexxa (Ondexxya) Market Report:
Andexxa (Ondexxya) Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the andexxa (ondexxya) market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the andexxa (ondexxya) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
